IP Library Granted Patent US 9,150,898
Granted Patent B2
US 9,150,898 · App. 14/448,792 · Granted Oct 6, 2015

Heterologous expression of Neisserial proteins

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,150,898
App. No.
14/448,792
Granted
Oct 6, 2015
Kind
B2
Abstract

Alternative and improved approaches to the heterologous expression of the proteins of Neisseria meningitidis and Neisseria gonorrhoeae are disclosed. These approaches typically affect the level of expression, the ease of purification, the cellular localization, and/or the immunological properties of the expressed protein.

Claims (14)

1. A method of expressing an E. coli lipidated protein comprising

a) providing an E. coli host cell containing a nucleic acid encoding a heterologous leader peptide operably linked to a coding sequence for the protein, wherein the protein comprises i) a sequence having greater than 80% sequence identity to SEQ ID NO: 634; or ii) a fragment of at least 14 consecutive amino acids from SEQ ID NO: 634, wherein the E. coli host cell is capable of lipidating the protein and the heterologous leader peptide directs lipidation in the E. coli host cell;

b) expressing of the protein under conditions where the protein is lipidated at an N-terminal cysteine.

2. The method of claim 1 , wherein the protein comprises (i).

3. The method of claim 2 , wherein the sequence has greater than 90% sequence identity to SEQ ID NO: 634.

4. The method of claim 2 further comprising c) isolating the E. coli lipidated protein from the E. coli host cell.

5. The method of claim 4 further comprising d) formulating an immunogenic composition with the E. coli lipidated protein isolated from the E. coli host cell.

6. The method of claim 5 , wherein the immunogenic composition further comprises an alum adjuvant.

7. The method of claim 1 , wherein the protein comprises (ii).

8. The method of claim 7 , wherein the fragment includes 20 or more contiguous amino acids from SEQ ID NO: 634.

9. The method of claim 8 , wherein the fragment includes 50 or more contiguous amino acids from SEQ ID NO: 634.

10. The method of claim 8 further comprising c) isolating the E. coli lipidated protein from the E. coli host cell.

11. The method of claim 10 further comprising d) formulating an immunogenic composition with the E. coli lipidated protein isolated from the E. coli host cell.

12. The method of claim 11 , wherein the immunogenic composition further comprises an alum adjuvant.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2015
From: ARICO, MARIA BEATRICE; COMANDUCCI, MAURIZIO; GALEOTTI, CESIRA; MASIGNANI, VEGA; GIULIANI, MARZIA MONICA; PIZZA, MARIAGRAZIA
To: CHIRON S.R.L.
Reel/Frame 036292/0710 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2015
From: NOVARTIS VACCINES AND DIAGNOSTICS SRL
To: NOVARTIS AG
Reel/Frame 036319/0711 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2015
From: NOVARTIS AG
To: GLAXOSMITHKLINE BIOLOGICALS SA
Reel/Frame 036319/0716 →
CHANGE OF NAME Recorded Aug 10, 2015
From: CHIRON S.R.L.
To: NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.
Reel/Frame 036324/0894 →